Glucose-Responsive Swallowable Insulin: A Novel Paradigm in Diabetes Management
Diabetes Management
DOI:
https://doi.org/10.33687/ricosbiol.03.011.91Keywords:
Glucose-responsive insulin, oral insulin delivery, nanocarriers, phenylboronic acid, diabetes management, polymeric micelles, smart drug deliveryAbstract
The global prevalence of diabetes mellitus has necessitated the exploration of innovative therapeutic strategies that enhance patient compliance and optimize glycemic control. Conventional insulin therapy, though effective, often poses challenges due to invasive administration, fluctuating absorption, and limited patient adherence. The development of a glucose-responsive swallowable insulin system represents a transformative advancement in diabetes care. This approach integrates polymeric nanocarriers and bioengineered peptides that respond dynamically to blood glucose fluctuations, releasing insulin in a controlled and physiological manner. Polymeric micelles, hydrogels, and phenylboronic acid-modified nanocarriers have shown remarkable glucose sensitivity, making them potential candidates for oral formulations. These systems are designed to remain stable in the gastrointestinal environment while releasing insulin upon sensing hyperglycemia. The incorporation of glucose oxidase-based feedback mechanisms further enhances precision by coupling enzymatic sensing with insulin release kinetics. This manuscript critically reviews molecular design strategies, in vitro and in vivo results, and translational challenges in developing glucose-responsive swallowable insulin. Statistical models were applied to evaluate the relationship between glucose concentration and insulin release kinetics, revealing a high degree of correlation (R² > 0.95) between predicted and observed values. The findings underscore the promise of swallowable insulin as a non-invasive, self-regulating, and patient-centered therapeutic alternative. Future studies should emphasize large-scale clinical validation, long-term stability, and integration with digital glucose monitoring platforms to ensure real-world applicability
Downloads
References
Al-Shammari, A. M., & Hussain, S. A. (2021). Recombinant insulin bioproduction: Current status and future perspectives. Bioprocess and Biosystems Engineering, 44 (8), 1651–1664. https://doi.org/10.1007/s00449-021-02552-4
Bakhshpour, M., Hashemi, M., & Ghaffari, M. (2023). Recombinant peptide-based oral drug delivery systems: Progress and prospects. European Journal of Pharmaceutics and Biopharmaceutics, 183 , 94–108. https://doi.org/10.1016/j.ejpb.2022.12.013
Chen, Y., Wang, F., Huang, Z., Wang, Z., & Zhang, Y. (2022). Smart nanocarriers for responsive and targeted delivery of therapeutic biomolecules. Advanced Drug Delivery Reviews, 188 , 114451. https://doi.org/10.1016/j.addr.2022.114451
Eom, H., Kim, J., Kang, J., Kim, H., & Lee, E. (2022). Bioinspired oral insulin delivery using mucoadhesive nanogels. ACS Applied Materials & Interfaces, 14 (45), 51234–51246. https://doi.org/10.1021/acsami.2c11579
Fonte, P., Araújo, F., Reis, S., & Sarmento, B. (2020). Oral insulin delivery: How far are we? Journal of Diabetes Science and Technology, 14 (4), 846–855. https://doi.org/10.1177/1932296820921745
Ghitman, J., Biru, E. I., Stan, R., & Iovu, H. (2020). Review of hybrid polymeric nanocarriers for drug delivery. Nanomaterials, 10 (3), 652. https://doi.org/10.3390/nano10030652
Gu, Z., Aimetti, A. A., Wang, Q., Dang, T. T., Zhang, Y., Veiseh, O., Cheng, H., Langer, R. S., & Anderson, D. G. (2013). Injectable nano-network for glucose-mediated insulin delivery. ACS Nano, 7 (5), 4194–4201. https://doi.org/10.1021/nn400630x
Hwang, J., Cho, H., Lee, H., Kim, J., & Han, S. (2021). Recombinant biopolymers for protein stabilization in nanocarriers. Advanced Healthcare Materials, 10 (6), 2001638. https://doi.org/10.1002/adhm.202001638
Kim, H., Park, J., & Na, K. (2021). Glucose-responsive polymeric micelles for controlled insulin delivery. Journal of Controlled Release, 329 , 1090–1102. https://doi.org/10.1016/j.jconrel.2020.10.034
Kouchak, M., & Asadian-Birjand, M. (2021). Recent advances in oral insulin delivery by nanocarriers. International Journal of Pharmaceutics, 598 , 120366. https://doi.org/10.1016/j.ijpharm.2021.120366
Li, M., Yu, M., Nanda, S., Song, W., & Chen, S. (2023). Recombinant insulin analogues: Structural stability and clinical perspectives. Biotechnology Advances, 67 , 108226. https://doi.org/10.1016/j.biotechadv.2023.108226
Li, Q., Sun, M., Yu, J., Li, T., & Gu, Z. (2023). Dual-responsive oral insulin delivery based on recombinant peptide hydrogels. Journal of Materials Chemistry B, 11 (12), 2701–2712. https://doi.org/10.1039/d2tb02780a
Li, Y., Hu, X., Zhang, Y., Liu, X., & Wang, Y. (2023). Smart glucose-responsive nanoparticles for controlled insulin release. Chemical Engineering Journal, 468 , 143629. https://doi.org/10.1016/j.cej.2023.143629
Liu, C., Zhang, J., Li, X., Zhang, H., & Liu, C. (2021). Phenylboronic acid-functionalized nanoparticles for glucose-responsive insulin release. Biomacromolecules, 22 (7), 2732–2743. https://doi.org/10.1021/acs.biomac.1c00385
Liu, Y., He, L., Zhang, Y., Wang, F., & Li, J. (2023). Recombinant biomaterials in oral peptide delivery. Frontiers in Bioengineering and Biotechnology, 11 , 1153942. https://doi.org/10.3389/fbioe.2023.1153942
Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in oral biologics delivery. Nature Reviews Drug Discovery, 13 (9), 655–672. https://doi.org/10.1038/nrd4368
Soni, R., & Yadav, K. S. (2021). Nanogels as smart drug delivery systems: A comprehensive review. Journal of Controlled Release, 338 , 627–644. https://doi.org/10.1016/j.jconrel.2021.08.054
Wang, J., Ye, Y., Yu, J., Kahkoska, A. R., & Gu, Z. (2018). Developing glucose-responsive micro- and nanocarriers for diabetes therapy. Nature Reviews Drug Discovery, 17 (8), 611–629. https://doi.org/10.1038/nrd.2018.97
Wang, Y., Cheng, R., Meng, F., Deng, C., & Zhong, Z. (2016). Responsive polymeric micelles for cancer and diabetes therapy. Journal of Controlled Release, 240 , 349–367. https://doi.org/10.1016/j.jconrel.2016.01.009
Xu, J., Wang, Z., Li, Y., Huang, J., & Yao, H. (2022). Mucoadhesive nanoparticles for oral insulin delivery: Design and performance. European Journal of Pharmaceutics and Biopharmaceutics, 170 , 138–147. https://doi.org/10.1016/j.ejpb.2021.12.003
Yu, J., Zhang, Y., & Gu, Z. (2020). Stimuli-responsive insulin delivery systems. Accounts of Chemical Research, 53 (2), 321–330. https://doi.org/10.1021/acs.accounts.9b00548
Yu, M., Li, M., & Gu, Z. (2022). Bioinspired feedback systems in glucose-responsive insulin delivery. Advanced Materials, 34 (13), 2107053. https://doi.org/10.1002/adma.202107053
Zhang, Y., Yu, J., Kahkoska, A. R., & Gu, Z. (2022). Glucose-responsive insulin delivery systems: From molecular design to clinical applications. Advanced Drug Delivery Reviews, 182 , 114120. https://doi.org/10.1016/j.addr.2021.114120
Zhang, Z., Kuang, Y., Zhang, H., Liu, S., & Xiao, Y. (2020). Smart polymers in controlled release of protein therapeutics. Progress in Polymer Science, 109 , 101289. https://doi.org/10.1016/j.progpolymsci.2020.101289
Zhang, T., Wu, J., Zhao, H., Li, X., & Zhang, G. (2022). Glucose-oxidase integrated nanocarriers for self-regulated insulin delivery. ACS Nano, 16 (5), 8561–8575. https://doi.org/10.1021/acsnano.2c03345
Schiavo, G., Matteoli, M., & Montecucco, C. (2000). Neurotoxins affecting neuroexocytosis. Physiological Reviews, 80(2), 717–766. https://doi.org/10.1152/physrev.2000.80.2.717
Tao, L., Zhang, J., Meraner, P., Tovaglieri, A., Wu, X., Gerhard, R., Zhang, X., Stallcup, W. B., Miao, J., He, X., Hurdle, J. G., Breault, D. T., Brass, A. L., & Dong, M. (2016). Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature, 538(7625), 350–355. https://doi.org/10.1038/nature19799
Uzal, F. A., Freedman, J. C., Shrestha, A., Theoret, J. R., Garcia, J., Awad, M. M., Adams, V., Moore, R. J., Rood, J. I., & McClane, B. A. (2014). Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. Future Microbiology, 9(3), 361–377. https://doi.org/10.2217/fmb.13.168
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., Jenkin, G., Jensen, W., Kim, Y.-S., Yoshida, J., Gabryelski, L., Pedley, A., Eves, K., Tipping, R., Guris, D., … OPT-80-004 Clinical Study Group. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. New England Journal of Medicine, 376(4), 305–317. https://doi.org/10.1056/NEJMoa1602615
Additional Files
Published
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author, Dr. Rehan Haider, upon reasonable request. All data generated or analyzed during this study were derived from previously published research articles cited within the manuscript. No new experimental data were produced. Supplementary datasets, including statistical modeling outputs and graphical figures, are archived in the Riggs Pharmaceuticals Molecular Pharmaceutics Research Repository and can be accessed by contacting the Department of Pharmacy, University of Karachi.
Issue
Section
Categories
License
Copyright (c) 2025 Naqvi R., Ahmed Z., Zameer S.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
